Physician profile
Peter Andrew Bailey
NPI 1871974808
$6,809.68
in general payments reported to CMS, 2019-2025
37 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $287 · 2022: $930 · 2023: $1,311 · 2024: $1,437 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,950.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,147.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,054.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $789.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $505.25 | 2019-2025 | Vraylar, Qulipta |
| Pfizer INC. | $478.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $311.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $242.73 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $221.10 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $198.47 | 2019-2025 | |
| Abbott Laboratories | $184.81 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $153.53 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $145.89 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $143.08 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $133.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.65 | 2022-2025 | Xifaxan, Trulance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.